Connection

W. Garvey to Weight Loss

Back to Details
This is a "connection" page, showing publications W. Garvey has written about Weight Loss.
W. Garvey
Connection Strength
5.278
Weight Loss
  1. Diagnosing Obesity as a First Step to Weight Loss: An Observational Study. Obesity (Silver Spring). 2020 12; 28(12):2305-2309.
    View in: PubMed
    Score: 0.588
  2. COMMENTARY FROM THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS ON THE U.S. PREVENTIVE SERVICES TASK FORCE RECOMMANDATIONS REGARDING WEIGHT LOSS INTERVENTIONS. Endocr Pract. 2019 04; 25(4):394-395.
    View in: PubMed
    Score: 0.531
  3. Ablation of the Duodenal Mucosa as a Strategy for Glycemic Control in Type 2 Diabetes: Role of Nutrient Signaling or Simple Weight Loss. Diabetes Care. 2016 12; 39(12):2108-2110.
    View in: PubMed
    Score: 0.450
  4. Weight maintenance: challenges, tools and strategies for primary care physicians. Obes Rev. 2016 Jan; 17(1):81-93.
    View in: PubMed
    Score: 0.416
  5. Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action. Curr Obes Rep. 2015 Jun; 4(2):287-302.
    View in: PubMed
    Score: 0.405
  6. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014 Dec; 37(12):3309-16.
    View in: PubMed
    Score: 0.387
  7. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012 Feb; 95(2):297-308.
    View in: PubMed
    Score: 0.318
  8. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022 10; 28(10):2083-2091.
    View in: PubMed
    Score: 0.169
  9. Examining the evidence for weight management in individuals with type 2 diabetes. Diabetes Obes Metab. 2022 08; 24(8):1411-1422.
    View in: PubMed
    Score: 0.165
  10. New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications. J Clin Endocrinol Metab. 2022 03 24; 107(4):e1339-e1347.
    View in: PubMed
    Score: 0.163
  11. Is Obesity or Adiposity-Based Chronic Disease Curable: The Set Point Theory, the Environment, and Second-Generation Medications. Endocr Pract. 2022 Feb; 28(2):214-222.
    View in: PubMed
    Score: 0.159
  12. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 04 13; 325(14):1403-1413.
    View in: PubMed
    Score: 0.152
  13. Exercise training and diet-induced weight loss increase markers of hepatic bile acid (BA) synthesis and reduce serum total BA concentrations in obese women. Am J Physiol Endocrinol Metab. 2021 05 01; 320(5):E864-E873.
    View in: PubMed
    Score: 0.151
  14. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care. 2020 05; 43(5):1085-1093.
    View in: PubMed
    Score: 0.141
  15. Changes in weight control behaviors and hedonic hunger in a commercial weight management program adapted for individuals with type 2 diabetes. Int J Obes (Lond). 2020 05; 44(5):990-998.
    View in: PubMed
    Score: 0.140
  16. Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study. Obesity (Silver Spring). 2017 05; 25(5):857-865.
    View in: PubMed
    Score: 0.116
  17. Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release. Diabetes Care. 2017 07; 40(7):856-862.
    View in: PubMed
    Score: 0.116
  18. EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS. Endocr Pract. 2016 11; 22(11):1277-1287.
    View in: PubMed
    Score: 0.110
  19. Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders. Postgrad Med. 2016 Aug; 128(6):591-7.
    View in: PubMed
    Score: 0.110
  20. New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach. Endocr Pract. 2013 Sep-Oct; 19(5):864-74.
    View in: PubMed
    Score: 0.090
  21. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opin Drug Saf. 2013 Sep; 12(5):741-56.
    View in: PubMed
    Score: 0.088
  22. Diet, insulin resistance, and obesity: zoning in on data for Atkins dieters living in South Beach. J Clin Endocrinol Metab. 2004 Sep; 89(9):4197-205.
    View in: PubMed
    Score: 0.048
  23. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2023 02; 25(2):468-478.
    View in: PubMed
    Score: 0.042
  24. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022 May; 28(5):528-562.
    View in: PubMed
    Score: 0.041
  25. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 01 11; 327(2):138-150.
    View in: PubMed
    Score: 0.040
  26. Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial. J Diabetes Complications. 2017 May; 31(5):891-897.
    View in: PubMed
    Score: 0.029
  27. Acylcarnitines as markers of exercise-associated fuel partitioning, xenometabolism, and potential signals to muscle afferent neurons. Exp Physiol. 2017 01 01; 102(1):48-69.
    View in: PubMed
    Score: 0.028
  28. Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care. 2015 Aug; 38(8):1567-82.
    View in: PubMed
    Score: 0.026
  29. Improved metabolic health alters host metabolism in parallel with changes in systemic xeno-metabolites of gut origin. PLoS One. 2014; 9(1):e84260.
    View in: PubMed
    Score: 0.023
  30. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012 Feb; 20(2):330-42.
    View in: PubMed
    Score: 0.020
  31. Dietary adherence during weight loss predicts weight regain. Obesity (Silver Spring). 2011 Jun; 19(6):1177-81.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.